Here's how the future of care delivery will take shape.
It's the most promising trend in healthcare today: the ability to analyze large data sets to pinpoint actionable information that can be analyzed to tailor personalized treatment regiments and activate preventative wellness -- but that's as hard as it sounds.
HIMSS Media during May will interview the experts, talk to thought leaders about the obstacles and opportunities precision medicine presents today.
The case for precision medicine has been made. Now, how do we make it happen?
The ROI is in no longer going about treatment by trial and error.
Poll reveals confidence in IT sector, while challenges remain in recruiting talent to capitalize on population health, precision medicine and more.
Targeted interventions have shown a modest ability to lower costs and have the potential to greatly improve cancer care.
Success in precision medicine has been largely dependent on thought leaders who are highly skilled interdisciplinary leaders.
Both terms get used to mean essentially the same thing but there are some subtleties that distinguish them.
Precision medicine tailors care, but it requires technology and interpreting genetic data, complexities that present a roadblock for physicians.
Machine learning advances go above and beyond what has presently been achieved in medicine, the findings showed.
Precision medicine is a disruptive technology that is moving from revolution to evolution into mainstream adoption.
Bryce Olson, healthcare strategist at Intel, shares how telling his physician to "sequence me" helped him kick cancer.
The promise of personalizing care is enormous but it will also require hefty investments to turn it into a reality.
Just as critical as understanding genomic data is getting insights about a patient's environment and lifestyle, says University of Colorado Assistant Professor Mustafa Ozkaynak.
Sam Hanna, associate dean of graduate and professional studies and program director in healthcare management at American University, discusses why workforce development is needed to use data and technology to create targeted therapies.
Pharma wants to be a part of value-based programs for risk-based arrangements with payers.
The healthcare industry wastes $2.5 billion per year on ineffective therapy, according to researchers.
At Renown Health, genomic testing and remote consulting meet for what's billed as a first-of-its-kind population health initiative.
The teams will collect, process and analyze EHR data of up to 3,000 patients to create personalized care plans for people with MS.
The pharma company will leverage Concerto's artificial intelligence-powered analytics capabilities to gain better oncology insights.